TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6323783
Drug: Two-drug combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug combination (ACNU . VCR, ADM . VCR)
Study: 6323783
Drug: Three-drug combination
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug combination (ACNU . CPA . VCR, ACNU . ADM . VCR)
Study: 27233251
Drug: Aminophylline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (75 mg administered intravenously 90 seconds after 99mTc-tetrofosmin injection)
Study: 24129130
Drug: Initial infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial infliximab treatment
Study: 24129130
Drug: Delayed infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Delayed infliximab treatment (in arms 1-3)
Study: 24129130
Drug: Post-discontinuation of
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discontinuation of infliximab
Study: 17283346
Drug: Ambulatory CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory CPAP titration
Study: 11445632
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (100 mg weekly intramuscular injections)
Study: 3064254
Drug: Veralipride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veralipride (1 tablet per day for 20 days)
Study: 24090379
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with simvastatin (40 mg/day) and ezetimibe (20 mg/day)
Study: 24090379
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with simvastatin (80 mg/day)
Study: 21355151
Drug: Du-moxibustion combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Du-moxibustion combined with western medicine (herb-partitioned spread moxibustion on the Governor Vessel between Dazhui (GV 14) and Yaoshu (GV 2))
Study: 14563190
Drug: Diuretics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics plus albumin (n = 63)
Study: 14563190
Drug: Albumin treatment
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin treatment (25 g/week)
Study: 14563190
Drug: Albumin treatment
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin treatment
Study: 10852611
Drug: 2.4 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mg/day of folic acid (FA), 50.0 mg/day of vitamin B6, 0.4 mg/day of vitamin B12
Study: 10852611
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day of folic acid (FA) or 17 mg/day of L-5-methyltetrahydrofolate, 50.0 mg/day of vitamin B6, 1.0 mg/day of vitamin B12
Study: 9583629
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) - subjects could select one product of their choice or were randomly assigned a product during the study weeks.
Study: 30182639
Drug: NSPT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSPT plus anti-oxidant gel formula (propolis)
Study: 30182639
Drug: NSPT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSPT plus chlorhexidine gel formula
Study: 27271087
Drug: Asenapine 5
Normalized name: asenapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 5 mg bid
Study: 27271087
Drug: Asenapine 10
Normalized name: asenapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 10 mg bid
Study: 22264742
Drug: Alcohol hand
Normalized name: Medpura Isopropryl Alcohol Hand Sanitizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol hand gel application every 60 minutes (q 60)
Study: 22264742
Drug: Alcohol hand
Normalized name: Medpura Isopropryl Alcohol Hand Sanitizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol hand gel application every 120 minutes (q 120)
Study: 22264742
Drug: Alcohol hand
Normalized name: Medpura Isopropryl Alcohol Hand Sanitizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol hand gel application only before lunch (q lunch)
Study: 12461065
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg single dose)
Study: 12461065
Drug: Clopidogrel (longer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (longer treatment, four days)
Study: 37142
Drug: Prifinium bromide
Normalized name: prifinium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prifinium bromide (90 mg daily before meals)
Study: 25046055
Drug: DPP-4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitor
Study: 21389739
Drug: Sub-Tenon (ST)
Normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Tenon (ST) posterior triamcinolone injection (ST group)
Study: 15151523
Drug: Fosfluconazole (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfluconazole (1000 mg intravenous bolus injection)
Study: 8871872
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) therapy
Study: 17900941
Drug: Bur treatment
Normalized name: bur oak pollen extract
DrugBank: Quercus macrocarpa pollen (DB10738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bur treatment
Study: 30689222
Drug: T3 infusion
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3 infusion for eight hours
Study: 30689222
Drug: T4 infusion
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 infusion for eight hours
Study: 28488462
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (Group S)
Study: 21392851
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.2 mg/dL)
Study: 17101640
Drug: Pioglitazone (15-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15-45 mg/d)
Study: 17101640
Drug: Glimepiride (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1-4 mg/d)
Study: 9416856
Drug: Intravenous pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pulse cyclophosphamide (CYC) with prednisone (group A)
Study: 29486367
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 150,000 IU vitamin D3
Study: 29486367
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 5000 IU vitamin D3
Study: 28069076
Drug: 55-g rye
Normalized name: Rye
DrugBank: Rye (DB10564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 55-g rye porridge
Study: 18979160
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 300,000 IU cholecalciferol
Study: 15959426
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate 200 mg
Study: 15959426
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate 200 mg and Vitamin E 400 IU
Study: 12773957
Drug: Transdermal 17beta
Normalized name: 17beta oestradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta oestradiol
Study: 12773957
Drug: Oral ethinyl
Normalized name: ethinyl estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ethinyl oestradiol, conjugated equine oestrogen, oestradiol valerate
Study: 12773957
Drug: Oral oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestrogen
Study: 12773957
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen
Study: 8568424
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser in the upper cervical region and deep friction massage in the lower cervical/upper thoracic region, twice/wk for 3 wk
Study: 1814714
Drug: Glass ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glass ionomer cement (Fuji II/G‐C Dental)
Study: 1814714
Drug: Sandwich restoration
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandwich restoration (Lining Cement/G‐C Dental)
Study: 31669890
Drug: Low-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interleukin-2 (ld-IL2) combined with conventional therapy in 35 patients
Study: 20558004
Drug: Crystalloid (Hartmann's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid (Hartmann's solution)
Study: 17401606
Drug: Long-acting medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting medications for ADHD
Study: 7514366
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg of risperidone
Study: 1379883
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of haloperidol
Study: 20180789
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 60 mg before breakfast
Study: 20180789
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 60 mg before lunch
Study: 20180789
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 60 mg before dinner
Study: 20180789
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 60 mg before evening snack
Study: 8942890
Drug: 0.005% latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% latanoprost applied topically once daily for 12 months
Study: 28660441
Drug: Paclitaxel-resveratrol drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel-resveratrol drug matrix-coated balloon catheter (DCB)
Study: 15040645
Drug: Symptom profile
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom profile and side effects from antihypertensive drugs
Study: 15040645
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy compliance
Study: 8042129
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral therapy for gonorrhea (cefixime, ciprofloxacin, ofloxacin)
Study: 8042129
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral therapy for chlamydia (azithromycin)
Study: 8042129
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral therapy for chancroid (azithromycin)
Study: 8042129
Drug: Outpatient therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient therapy for pelvic inflammatory disease (ofloxacin and either clindamycin or metronidazole)
Study: 8042129
Drug: Patient-applied therapy
Normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient-applied therapy for genital warts (podofilox)
Study: 8042129
Drug: Syphilis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syphilis therapy
Study: 3542851
Drug: Zidometacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidometacin (400 mg p.o.)
Study: 3542851
Drug: Zidometacin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidometacin (600 mg rectal)
Study: 19299776
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg
Study: 11179983
Drug: Low M
Normalized name: Peak Flow Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low M (omeprazole 20 mg twice daily, amoxycillin 1,000 mg twice daily, metronidazole 400 mg twice daily)
Study: 6141114
Drug: Loprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loprazolam (1 mg)
Study: 30944068
Drug: Drug Coated
Normalized name: Drug coated stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Coated Balloon (DCB; coated with paclitaxel)
Study: 25369243
Drug: Atomoxetine 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 1.2 mg/kg/day
Study: 19580719
Drug: Low-flow AS
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow AS (defined as stroke volume index <22 ml/m²)
Study: 9480993
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at doses of 5, 20, or 80 ppm
Study: 30056389
Drug: Screening test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening test indicated aspirin
Study: 15313296
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% gel
Study: 7555484
Drug: Policosanol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol (5 mg, twice a day for 12 weeks)
Study: 7293522
Drug: Naprosyn 500
Normalized name: Naprosyn 500mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naprosyn 500 mg suppositories
Study: 7293522
Drug: Naprosyn tablets
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naprosyn tablets
Study: 24976429
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 12 weeks
Study: 21352079
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg/day) plus Telmisartan (80 mg/day)
Study: 15042114
Drug: Eprosartan monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan monotherapy
Study: 11504275
Drug: AP1903 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1903 0.01 mg/kg
Study: 11504275
Drug: AP1903 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1903 0.05 mg/kg
Study: 11504275
Drug: AP1903 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1903 0.1 mg/kg
Study: 11504275
Drug: AP1903 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1903 0.5 mg/kg
Study: 20042925
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration
Study: 9360205
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration followed by Lactobacillus casei strain GG
Study: 8285751
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG 10(8) colony forming units twice a day for two weeks
Study: 29098841
Drug: Methotrexate tablets
Normalized name: Methotrexate Tablets
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate tablets (chemical medicine group)
Study: 10708052
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (zidovudine + lamivudine + ritonavir)
Study: 10708052
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy (zidovudine + lamivudine)
Study: 8403956
Drug: Continuous nebulization
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nebulization of albuterol (0.3 mg/kg/hr)
Study: 8403956
Drug: Intermittent nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nebulization of albuterol (0.3 mg/kg over 20 mins every hour)
Study: 8403956
Drug: Continuous nebulization
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nebulization of albuterol
Study: 8403956
Drug: Intermittent nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nebulization of albuterol
Study: 3511936
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily theophylline
Study: 9040452
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg)
Study: 30231787
Drug: Oral fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluids 6 hours postoperatively
Study: 28375647
Drug: Once-daily triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 μg/62.5 μg/25 μg; ELLIPTA inhaler)
Study: 19590476
Drug: G-ER 1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-ER 1800 mg once-daily administered in the evening
Study: 19590476
Drug: G-ER 1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-ER 1800 mg asymmetric divided dose (600 mg AM and 1200 mg PM)
Study: 19590476
Drug: Placebo G-ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo G-ER
Study: 31162017
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg/day for 6 weeks
Study: 11071065
Drug: Fluvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin treatment for 16 weeks
Study: 9052620
Drug: 5‐fluorouracil (5‐FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU) group: five subconjunctival injections of 5 mg 5‐FU, starting from day 8 after surgery, one injection per week.
Study: 9052620
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: no injections.
Study: 8448099
Drug: 18-gauge Tuohy-Schliff
Normalized name: Schiff
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18-gauge Tuohy-Schliff needle/20-gauge catheter combination (group 1)
Study: 8448099
Drug: 20-gauge Quincke
Normalized name: QUINCE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-gauge Quincke point needle/24-gauge catheter combination (group 2)
Study: 3512898
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy with biological feedback (BFB) (group 2)
Study: 30940872
Drug: Ultra-low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low dose protocols with 400 µm voxel size and 7.4 mAs
Study: 23930843
Drug: HFM-AB1 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFM-AB1 (500 ml antioxidant beverage 1; apple, grape, blueberry and pomegranate juices and grape skin, grape seed and green tea extracts)
Study: 23930843
Drug: HFM-AB2 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFM-AB2 (500 ml antioxidant beverage 2; pineapple, black currant and plum juices)
Study: 23930843
Drug: HFM-PB (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFM-PB (500 ml placebo beverage, free from fruit)
Study: 19581564
Drug: Moderate-dosage bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dosage bilateral ECT
Study: 15037554
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide synthase inhibitor (L-NMMA)
Study: 8848192
Drug: Selective anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective anesthesia of the right hemisphere during right intracarotid barbiturate infusion
Study: 25494658
Drug: Essential oil
Normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oil (EO) mouthrinse (40 mL/day for 90 days)
Study: 25494658
Drug: Placebo mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouthrinse (40 mL/day for 90 days)
Study: 24070431
Drug: DPV 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPV 0.05% gel
Study: 18080351
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo gel
Study: 17241844
Drug: Universal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal placebo gel
Study: 17632215
Drug: Olanzapine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-20 mg/d)
Study: 12442883
Drug: Amisulpride (200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (200-800 mg/d)
Study: 9744776
Drug: Low-dose carboplatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose carboplatin (CG-Calvert formula)
Study: 4043678
Drug: Clonidine 0.3
Normalized name: CLONIDINE 0.3MG/24HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.3 mg
Study: 31538430
Drug: Very short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Very short-term exposure to PM10 exceeding 100 µg/m3 for 2 hours
Study: 28558817
Drug: Aerobic exercise,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic exercise, strength training, and physical therapy (3 months, biweekly 90-min sessions)
Study: 28558817
Drug: Aerobic exercise,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic exercise, strength training, and physical therapy
Study: 22086108
Drug: Intravaginal micronized
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal micronized natural progesterone (200 mg daily)
Study: 17126073
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg daily)
Study: 19571282
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg daily)
Study: 10930686
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Russian live attenuated and US inactivated trivalent influenza vaccines
Study: 10930686
Drug: Live vaccine
Normalized name: rubella virus live vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live vaccine alone
Study: 9778752
Drug: Inactivated vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated vaccine alone
Study: 10930686
Drug: Live vaccine
Normalized name: rubella virus live vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live vaccine (alone or in combination with inactivated vaccine)
Study: 10930686
Drug: Combination vaccines
Normalized name: Hepatitis vaccine combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination vaccines
Study: 9031444
Drug: Dalteparin (Fragmin)
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (Fragmin) 5000 i.u. once daily for 4 weeks
Study: 8081065
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D3 supplements (1.2 g calcium and 800 IU vitamin D3 daily)